valeant

BNET Resources

• sort by:
• Relevance
• Date
• Popularity

Valeant Receives Non-Approvable Letter from FDA for Labeling Application of Cannabinoid Cesamet™

COSTA MESA, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration for the company's application requesting labeling changes to its previously approved drug Cesamet CII nabilone. The FDA requested additional information to address concerns over potential class...

Tags: FDA, Valeant

Research articles 2005-12-30

Life Without Blockbusters: What Valeant's Woes Portend for Pharma

It's now a truism that the drug industry's "blockbuster model" has pretty much had its day. Much of Big Pharma is having a terrible time winning approval for new drugs and even keeping up sales of existing blockbusters, in part because their underlying rationale -- that pushing drugs into mass...

Tags: Pharmaceutical Company, Blockbuster, Drug, Valeant, David P. Hamilton

Blog posts 2008-05-05

Additional Resources

Valeant Reports Encouraging End of Treatment Results with Taribavirin at Treatment Week 48 in Phase IIb Study

-- Continues to Demonstrate Similar Efficacy to Ribavirin with Lower Anemia -- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals (NYSE:VRX) today reported results at end of treatment, week 48 analysis point in the Phase IIb clinical trial for its antiviral compound, taribavirin, a prodrug of ribavirin in development for...

Articles 2008-11-24

Valeant Pharmaceuticals Acquires DermaTech

-Purchase Expands Valeant's Dermatology Business in Australia- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has acquired DermaTech Pty Ltd, an Australian specialty pharmaceutical company focused on dermatology products marketed throughout Australia and overseas, for approximately AU$19 million, with customary adjustments for net asset...

Articles 2008-11-14

Valeant Pharmaceuticals to Present at Lazard Capital Markets 5th Annual Healthcare Conference

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the Lazard Capital Markets 5th Annual Healthcare Conference on Wednesday, November 19, 2008 at 11:00 a.m. EST. The conference will be held at The St. Regis, New York,...

Articles 2008-11-12

Valeant Pharmaceuticals to Present at 2008 Credit Suisse Phoenix Health Care Conference

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the 2008 Credit Suisse Phoenix Health Care Conference on Friday, November 14, 2008 at 9:30 a.m. MST. The conference will be held at the Arizona Biltmore Resort in...

Articles 2008-11-07

Valeant Pharmaceuticals Reports Third Quarter Financial Results

* New $200 Million Securities Repurchase Program Approved by Board ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced third quarter financial results for 2008. Total revenue was $168.4 million in the third quarter of 2008 as compared to $164.3 million in the third quarter...

Articles 2008-11-06

Hedge Fund Ups Advanced Medical Stake

Glaxo to Market Valeant's Seizure Drug; Core Valve Expands Trial HEALTHCARE A New York hedge fund has upped its stake in Santa Ana's Advanced Medical Optics Inc., a maker of eye surgery devices and contact lens solutions. Tremblant Capital Group now holds a 5% stake...

Articles 2008-11-03

Valeant Pharmaceuticals Announces Promotion Agreement for Diastat® AcuDial™

Further Enhances Relationship with GlaxoSmithKline ALISO VIEJO, Calif. -- Valeant Pharmaceuticals (NYSE:VRX) today announced that it has signed an agreement with GlaxoSmithKline (NYSE:GSK) for the promotion of Diastat[R] and Diastat[R] AcuDial[TM], the first and only FDA-approved, acute at-home medication for patients two years and older on stable antiepileptic...

Articles 2008-10-24

Valeant Pharmaceuticals to Announce 2008 Third Quarter Results on November 6, 2008

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it will host a conference call on Thursday, November 6, 2008 at 10:00 a.m. EST (7:00 a.m. PST) to discuss results for the 2008 third quarter. The dial-in number to participate on this call is (877) 295-5743,...

Articles 2008-10-22

Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine

Valeant Receives $125 Million Upfront ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has closed on its exclusive worldwide collaboration agreement with GlaxoSmithKline GSK for the investigational drug retigabine, a first-in-class neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory...

Articles 2008-10-17

Valeant Pharmaceuticals Completes Acquisition of Coria Laboratories, Ltd

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has completed its acquisition of Coria Laboratories, Ltd., a privately-held specialty pharmaceutical company focused on dermatology products in the United States. Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent...

Articles 2008-10-16

Valeant Pharmaceuticals Signs Agreement to Acquire Coria Laboratories, Ltd

Purchase Expands Valeant's U.S. Dermatology Business ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire Coria Laboratories, Ltd., a privately-held specialty pharmaceutical company focused on dermatology products in the United States. This transaction significantly expands Valeant's business in...

Articles 2008-09-17

DFB Sells Coria Labs to Valeant Pharmaceuticals

FORT WORTH, Texas, Sept. 17 /PRNewswire/ -- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., today announced that DFB has signed a definitive agreement to sell its dermatology division Coria Laboratories, Ltd. to Valeant Pharmaceuticals International . Under the terms of...

Articles 2008-09-17

Valeant Announces Presentation of Retigabine Data at the 8th European Congress on Epileptology

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that clinical data for retigabine from the Phase III RESTORE program will be presented at the 8th European Congress on Epileptology, which will be held at the Berlin Internationales Congress Centrum ICC in Berlin, Germany, September 21-24, 2008. ...

Articles 2008-09-15

Swedish pharmaceuticals company Meda AB complete acquisition of European operations of Valeant Pharmaceuticals

NORDIC BUSINESS REPORT-12 September 2008-Swedish pharmaceuticals company Meda AB complete acquisition of European operations of Valeant PharmaceuticalsC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Swedish speciality pharmaceuticals company Meda AB (OMX Stockholm: MEDA A) said on Friday (13 September) that it has completed its previously announced acquisition of the European operations...

Articles 2008-09-12

Meda: Acquisition of European Businesses from Valeant Completed

* Competition authorities have approved the acquisition of Valeant's business in Western and Eastern Europe. Meda now takes over the operation. * Meda gains - Russian entry with own organisation - Significant market synergies in Eastern Europe - Strengthened position in Western Europe, especially...

Articles 2008-09-12

Valeant Pharmaceuticals Completes Sale of Certain European Operations to Meda AB

ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has completed its sale of certain business operations located in Western Europe, Eastern Europe, and certain export markets to Meda AB, pursuant to the Acquisition Agreement entered into by Meda and Valeant on August 4, 2008. Valeant received...

Articles 2008-09-12

PEOPLE

Hirings, promotions and other moves at local businesses ARCHITECTURE Maria Martinico joined HKS Inc. in Irvine as global practice leader of commercial interiors. She will expand the firm's commercial interiors group. She has experience working for Maguire Properties Inc. and Valeant Pharmaceuticals International. ARTS &...

Articles 2008-09-08

EXECUTIVE SUMMARY

This past week's news from www.ocbj.com and other sources TOP STORIES Irvine's Broadcom Corp. is paying $192.8 million in cash for the digital TV chip business of Advanced Micro Devices Inc. The deal stands to expand Broadcom's business providing chips to makers of digital TVs. The business includes...

Articles 2008-09-01